论文部分内容阅读
目的研究肝动脉化疗栓塞术联合射频消融治疗肝癌患者的临床疗效。方法 85例肝癌患者,随机分为实验组(43例)与对照组(42例)。实验组患者实施肝动脉化疗栓塞术联合射频消融治疗,对照组患者实施肝动脉化疗栓塞术治疗。观察两组患者体征变化、不良反应发生及病情复发情况。结果实验组患者甲胎蛋白、谷丙转氨酶、肿瘤最大直径均优于对照组,差异具有统计学意义(P<0.05)。对照组患者不良反应发生率57.14%明显高于实验组34.88%,差异具有统计学意义(P<0.05)。对照组患者病情复发率50.00%明显高于实验组23.26%,差异具有统计学意义(P<0.05)。结论肝动脉化疗栓塞术联合射频消融治疗肝癌患者,可有效改善其临床症状,降低不良反应及疾病复发率,应在医学上推广使用。
Objective To study the clinical efficacy of transcatheter arterial chemoembolization combined with radiofrequency ablation in the treatment of patients with liver cancer. Methods Totally 85 patients with liver cancer were randomly divided into experimental group (43 cases) and control group (42 cases). Patients in the experimental group received hepatic arterial chemoembolization combined with radiofrequency ablation, and patients in the control group received hepatic arterial chemoembolization. Two groups of patients were observed signs of changes, the occurrence of adverse reactions and the recurrence of the situation. Results AFP, alanine aminotransferase and maximal diameter of tumor in experimental group were better than those in control group (P <0.05). The incidence of adverse reactions in control group was significantly higher than that in experimental group (57.14% vs 34.88%, P <0.05). The recurrence rate of 50.00% in control group was significantly higher than that in experimental group (23.26%), the difference was statistically significant (P <0.05). Conclusions Hepatic arterial chemoembolization combined with radiofrequency catheter ablation in the treatment of liver cancer patients can effectively improve its clinical symptoms and reduce the adverse reactions and disease recurrence rate and should be popularized in medicine.